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 Abstract 
Single nucleotide polymorphisms (SNPs) are the most common type of genetic variation 
known to be associated with many cancer types including ovarian cancer, which is one of the 
leading causes of morbidity and mortality among women. Our present approach is focused on 
investigating the impact of SNPs residing within 3’UTR s of genes associated with ovarian 
cancer (OC) on microRNA (miRNA) targeting and alteration in target gene pool using our in 
house programming tool RNA hybrid. From this study we obtained two putative miRSNPs 
rs61764370_kRAS-hsa-miR-223-5p and rs2069414_CDK2-hsa-miR-183-5p having 
functional significance in ovarian tumorigeneseis. Further investigation and target validation 
will help us to achieve a deeper insight into unexplored variables of gene regulations linked 
to development and progression of OC. 
Keywords: SNPs, miRNA, KRAS, CDK2, 3’UTRs 
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INTRODUCTION 
A disease in which number of the body’s cells after being malignant divide uncontrollably and 
spread into surrounding tissues is called as cancer. Cancer can begin virtually at any place within 
the human body. New cells are formed by cell growth and divided in order to fulfill body’s own 
requirement. Normal cells grow and upon being damaged, they die and are eventually replaced 
by new cells.  
Cancer can be defined as a cluster of diseases causing abnormal cell growth having the potential 
of spreading to various parts of the body known as metastatic tumor or malignant tumor. All 
tumors are generally not cancerous like benign tumors, as they don't spread to different parts of 
the body and are found to be localized at specific location. Unlike most benign tumors present 
within the body, benign brain tumors may have life threatening properties. Potential signs and 
symptoms comprise of a replacement lump, abnormal hemorrhage, a chronic cough, weight loss. 
In addition, cancerous cells have ability to avoid signals that usually warn cells to prevent 
dividing or starts a procedure referred as apoptosis, in which our body removes unnecessary 
cells. Cancer cells also can be able to control the normal cells and circulatory system that give 
nutrition to a tumor cell. For example, cancer cells can induce nearby normal cells to create 
blood vessels that provide the tumors oxygen and nutrients for their growth. Blood vascular 
system additionally remove waste product from tumors. Cancer cells are typically ready to evade 
the organs, tissue, and particular cells of immune system that defend our body from disease and 
alternative situations. Our immune system generally removes abnormal cells from our body but 
some cancer cells are not detected by the immune system. 
Cancer is caused by alteration of genes that control the mode of our cells performance, 
particularly the mode of growth and division. Characteristics of cancer cell include proliferation, 
cell division by activation of Ras or Myc oncogenes .Neoplasm suppression by Rb, inhibit 
growth and  suppress and inactivate pathways that leads to modify cells to die. Tumor cells 
activate specific gene pathway that make them immortal even in one generations of growth. 
Cancer cell has a property known as angiogenesis that is the capability to get their own nutrition 
and blood vascular system and by metastasis they can spread inside body for getting nutrient 
from other healthy tissue.   
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Cancers are grouped in to 5 major types by the type of tissue in which the cancer originates. 
 (1) Carcinoma: cancers of epithelial tissue, e.g. the skin or lining of tissue or internal organs. 
Various types of carcinoma are Adenocarcinomas, Transitional cells, Squamous cell carcinoma, 
Basal cells carcinoma etc. (2) Sarcoma: cancer that originates from connective tissues such as 
bone, cartilage and tendon. These are less common type than that of carcinoma. The major types 
of sarcoma are soft tissue sarcoma, bone sarcoma, rhabdomyosarcoma etc. (3) Lymphoma: 
Cancer originates from cells of immune system such as lymphatic system where the immune cell 
starts diving abnormally in form of tumors. (4) Leukemia: cancer originates from blood forming 
cells such as bone marrow. In this type of cancer, the number of white blood cell increases in 
number. (5) CNS cancer: cancer of central nervous system i.e. tissue of brain and spinal cord. 
 
There are over one hundred totally different known types of cancers diagnosed among humans 
such as hepatic cancer, pancreatic cancer, kidney cancer, cervical cancer, breast cancer, brain 
cancer and ovarian cancer etc. The most death causing cancers among females are breast, colon, 
endometrial, lung, cervical and ovarian cancer. 
Ovarian cancer: is originate from cells of ovaries. Risk factors include infertility, medication 
for fertility, and increase body weight .The women have a family history of ovarian cancer have 
more chance of developing ovarian cancer. Ovarian cancer have hereditary effects. Hereditary 
ovarian cancer may have a less proportion of all cases of ovarian cancer. 
 Ovarian cancer is tough to detect at early stage because there are no specific symptoms. 
Detection include examination of pelvic region, X-ray tests, pelvic ultrasound and about one 
hundred twenty five test of the ovary. Most ovarian carcinoma growth in women are benign 
having fluid-filled cysts. The sterile women have high risk of ovarian cancer. Women have 
increase risk of ovarian cancer those start ovulation at a younger age or have menopause at a 
very older age.  Hormone therapy after climacteric, fertility medication, and fleshiness increase 
risk of cancer. 
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Ladies with mutations in BRCA1 or BRCA2 have higher probability of developing this disease. 
Ovarian cancer is the most common form of cancer among women. Among 5 main subtypes of 
ovarian cancer, serous is commonest one. These tumors are believed to begin within the covering 
cell of the ovaries, most of cases it may form at the Fallopian tubes. Less common kinds of 
ovarian cancer include germ cell tumors and sex cord stromal tumors. A diagnosis of ovarian 
cancer is confirmed through examining histology of affected tissues. 
Ovarian tumors starts from 3 common types of cell. 
Epithelial ovarian cancer: Developing from the covering cells of the ovary. Most of the 
epithelial ovarian tumors are benign type. There are many categories of benign epithelial tumor, 
serous adenomas, mucinous adenomas and Brenner tumors. Cancerous animal tissue tumors are 
carcinomas - indicating they start within the lining of ovarian tissue. These are one of the most 
dangerous among different kinds of ovarian cancers. Sadly epithelial ovarian cancer is found in 
70% of women and diagnosis is very less until the illness is at highly developed stage. 
Ovarian germ cell tumor: The ova or eggs manufacture ovarian germ cell tumor. These cell 
have some properties of cancerous tumor and life threatening property .Generally germ cell 
tumors are non-cancerous in nature dysgerminomas, endodermal sinus tumors and maturing 
teratomas are the most common germ cell malignancies. 
Ovarian stromal cancers: Ovarian stromal cancer developed from connective tissue. It starts 
from the cells that carry both the ovaries. Estrogen and progesterone are manufacture by them. 
Granulosa-theca tumors and Sertoli-Leydig cell tumors are most common types of stromal 
cancer. 
Players behind Ovarian Oncogenesis: 
Behind Ovarian cancer there are mainly 3 factors -  
· Environmental factors (Advance age, Infertility, Endometriosis, Obesity, Family history), 
Genetic factors and epigenetic factors. 
· Generally Genetic factors  tends to alter the DNA sequence by mutation(deletion, 
duplication, insertion etc), ex-SNP 
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· Epigenetic factors don’t change the sequence of DNA .Ex- DNA methylation, histone 
modification and microRNA. 
 
                  
Environmental 
factors Epigenetic  factorsGenetic  factors
Change in DNA sequence
•Mutation 
•Insertion
•Deletion
Without change inDNA
sequence
•DNA Methylaton
•Histone modification
 
                                     Figure-1- Causes of ovarian cancer 
microRNA:  
microRNA is known as small non-coding RNA, about 20-22 nucleotides length. In case of 
plants, animals, and some viruses have these types non coding RNA. RNA silencing machinery 
and post-transcriptional regulation of gene expression by degrading or silencing the target 
transcript is carried out ,by microRNA. Also in case of different biological processes like cell 
cycle, apoptosis, cell proliferation, carcinogenesis, metastasis and chemo resistance, microRNA 
plays an important role. In case of progression of cancers in human like ovarian cancer 
microRNA plays a vital role and it is proved that microRNAs act as tumor suppressor gene or 
oncogene. (Kinose et al., 2014) 
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SNPs 
Single nucleotide polymorphisms, shortly named as SNPs. These are the most common type of 
genetic variation found in the genes. SNPs are population specific. SNP leads to change in a 
single DNA building block known as a nucleotide. Example, a SNP can substitute the nucleotide 
(G) with the nucleotide pyrimidine (A) at a certain stretch of DNA. A Single nucleotide change 
can have substitution, deletions or insertion effect in a nucleotide sequence. In case of coding 
region as well as in case of non-coding region of genes the SNPs are found. SNPs present in 
coding region of gene can alter the sequence of amino acid.  
SNPs can be located in non coding region beside the CDS such as at 3’ UTR, 5’UTR or in intron 
region. SNPs present in the UTR region are known to affect the functionality of target transcript, 
affecting the RNA interference mechanism operated by miRNAs. SNPs located within the 3 
ÚTR are importance to unveil the possible role of these SNPs in disease pathogenesis as these 
are the hubs of miRNA binding and target gene regulations. SNPs located within 3/UTR can 
interfere with miRNA targeting either by creating or destroying the target site, thereby altering 
the expression of targeted genes. For instance, a SNP, rs4846049 (G>T) located within 3/UTR of 
5,10-methylenetetrahydrofolate reductase (MTHFR) is identified to increase the risk of coronary 
heart disease through modifying miRNA binding for hsa-miR-149 (Wu et al., 2013). 
Our present study is focused on investigating the impact of SNPs residing within 3/UTRs of 
genes associated with Ovarian cancer(OC) on miRNA targeting and change in target gene pool 
which will assist us to achieve a deeper insight for exploring variables of gene regulations linked 
to development and progression of OC. To achieve this goal, the aberrantly expressed 
up‐regulated miRNAs and SNPs with 25 nucleotide flanking on each side of the polymorphic 
base reported in OC are used for predicting targets for both wild type and mutant alleles followed 
by identifying the potential miRSNPs by using stringent parameters of miRNA targeting such as 
seed topology, change in the hybridization energy, wobble base pairing within seed site, 3/ 
complementarity, 3/ supplementary sites and  site accessibility that might be contributing to 
disease susceptibility and might give a clue towards tumor progression. 
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REVIEW OF LITERATURE 
Cancer is a class of diseases caused by abnormal cell growth. There are different types of cancer 
(about 100 types). When damaged cells divide uncontrollably to form lumps or masses of tissue 
termed as tumors, these enhance the starting of cancer. The digestive, nervous, and circulatory 
systems, excretory system are affected by the tumor and change the body function.A tumor is  
said as metastasized when it successfully spread to other parts of the body and grows, attacking 
and destroying other healthy tissues(Klein, 2008). This process itself titled as metastasis, and it is 
very tough to control. Cancer leads to uncontrollably growth without termination. Normal cells 
in the body follow a systematic pathway of growth, division, and finally death by apoptosis. 
Apoptosis is known as Programmed cell death and when cancer initiates to form this procedure 
breaks down. Like normal cells, cancer cells do not involved in programmatic death and it 
continue to grow and divide rapidly. This results to a mass of abnormal cells that grows and 
divides out of control. 
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RESISTING
CELL DEATH 
INDUCING
ANGIOGENESIS
METASTASIS LIMITLESS
REPLICATIVE
POTENTIAL
GENOMIC 
INSTABILITY
&
MUTATION
CANCER
EVADING 
GROTH 
SUPRESSOR
 
                                      Figure 2- Characteristics of tumorigeneseis 
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Cancer is one type of complex group of diseases with many probable reason. There are various 
reasons of cancer like genetic factor and epigenetic factors which can be control by lifestyle of 
the individual like chewing of tobacco, unhealthy diet, various types of infection and exposure to 
different types of chemicals and radiation etc. There are some environmental factors including 
infertility, aging, tobacco, some viruses and bacteria, exposure to sun and radiation, different 
chemicals, certain hormones, alcohol, diet, lack of physical activity, family history of cancer, 
obesity, use of certain drugs etc. 
Most occurring human cancer types are –  
Leukemia: Known as blood cancer. In leukemia the white blood cells are increase in number. 
But some leukemia found in other blood cell. It affects immunity system of our body. Different 
kinds of leukemia have different treatment.  
Hepatic cancer: Also known as liver cancer. Liver cancer starts in cells of liver. abdominal pain, 
yellow skin, nausea and liver dysfunction are the basic symptoms of liver cancer. 
 Lung cancer: Lung cancer starts in cells of lungs. There are three main types of lung cancer. 
Small Cell Lung Cancer, Non-Small Cell Lung Cancer, and Lung Carcinoid Tumor.Most 
common type of lung cancer is Non-Small Cell Lung Cancer. Non-small cell lung cancers are 
about 85%. Subtypes of non-small cell lung cancer are Squamous cell carcinoma, large cell 
carcinoma, adeno-carcinoma. Small Cell Lung Cancer-Small cell lung cancer also titled as oat 
cell cancer. About 10%-15% of lung cancers are this type. This type of lung cancer spread 
quickly to other parts. Lung Carcinoid Tumor- 5% of lung cancers is lung carcinoid tumors. Also 
known as lung neuroendocrine tumors. The growth of this tumor is very slow and spread rarely. 
Pancreatic cancer: It begins in the pancreas and most are of exocrine tumor types. Pancreatic 
neuroendocrine tumors, or islet cell tumors are less common type can have a better prognosis. 
Breast cancer: Initiates from the tissue of breast. Lump in the breast, change in shape, fluid 
coming from the nipple, dimpling of the skin, and red scaly patch of skin are the symptoms of 
breast cancer. 
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Ovarian cancer:  Ovarian cancer is the 5th most cancer among women. It has a most important 
role in morbidity and mortality with little variation in survival rates over past 30 years. Bloating, 
abdominal pain and discomfort, difficulty in eating, fatigue, indigestion, heartburn, constipation, 
early satiety, and possibly urinary symptoms are important symptoms of ovarian cancer. The 
etiology of ovarian cancer is not properly known.  
Contributing factors of ovarian cancer are stimulation of extreme gonadotropin and androgen. 
Exposure of the ovaries to pelvic pollutants and carcinogens has an important role in the 
pathogenesis of ovarian cancer. Family history of disease plays an important factor of the 
disease. Mutations in the BRCA1 and BRCA2 genes responsible for ovarian cancer (Lancaster et 
al., 2015). Refractory infertility null parityare are the risk factors in ovarian cancer. Taking oral 
contraceptives and tubal ligation are the protecting factors. Use of oral contraceptive with 5 years  
continiously women may decrease  their risk of ovarian cancer about in half (Holschneider and 
Berek, 2000). 
Types of Ovarian Carcinoma 
A wide variation of histological types of ovarian tumors is identified. Based on histogenetic 
principles the histological classification of ovarian tumors classified by the World Health 
Organization .These histological subtypes include epithelial ovarian tumors like endometrioid, 
serous, mucinous and clear cells. 
The majority of malignant ovarian tumors are epithelial ovarian tumors, which further grouped 
into histological types such as serous, mucinous, endometrioid and clear cell. Clear cell and 
endometrioid carcinomas have a tendency to remain confined to ovary. In contrast Clear cell and 
endometrioid carcinomas are highly related with endometriosis. Clear cell and endometrioid 
carcinomas may be the unique histological types linked with serous carcinomas with respect to 
stage distribution and association with endometriosis (Kaku et al., 2003) 
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Signs and symptoms  
There are various signs and symptoms of ovarian cancer .The signs and symptoms of ovarian 
cancer are frequently unseen in early stage. They may be indirect, even when they do at present. 
Before being known and diagnosed, symptoms will be present for several months in many cases. 
They may be primarily misdiagnosed as a condition like irritable bowel syndrome. The primary 
stages of ovarian cancer tend to be painless unless the growing mass results ovarian torsion.  
Bloating, abdominal pain and discomfort, difficulty in eating, fatigue, indigestion, heartburn, 
constipation, early satiety, and possibly urinary symptoms are distinctive symptoms of ovarian 
cancer .These symptoms are initiated by a mass pressing on the other abdominopelvic organs. 
The presenting indications can include severe abdominal pain, irritation of the peritoneum, or 
hemorrhage in case of adolescents or children with ovarian tumors. Development and a growth 
of fluid in the abdomen start when the cancer becomes more advanced. Anything that raises a 
person's chance of developing cancer is called as a risk factor. Some risk factors affect the 
development of cancer directly and some indirectly cause cancer. Some people mayn’t develop 
cancer with some risk factors, while others can develop cancer with no known cancer risk 
factors. Some known risk factors of ovarian cancer include- 
Age 
Age is an important factor of ovarian cancer.  Women with increasing age have increasing risk of 
developing ovarian cancer. Women of all ages have a risk of ovarian cancer, women over fifty 
have more possible to develop ovarian cancer. Within the range of 32-55 age 68 % of women 
with ovarian cancer are found. 
Family history 
Women with family history have more chance to have disease .Women have 3 times higher risk 
of develop the disease with a first-degree relative (like mother, daughter, or sister) with ovarian 
cancer. When 2 or additional first-degree relatives are diagnosed with ovarian cancer the risk 
will increase. 
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Genetic factors 
Because of genetic mutation about 10% -15% of ovarian cancers happen. There are several 
genetic condition related to an increased risk of ovarian cancer. The women with an epithelial 
ovarian cancer have become readily apparent with identification of the BRCA1, and BRCA2 
genes. Women have a high risk of ovarian cancer, who had mutation in either of these genes 
(11–60%). These are the highly lethal cancers. In families with a strong history of ovarian 
cancer, BRCA1and BRCA2 mutation testing has become the accepted standard of care. (Gau et 
al., 2015). Mutations can alter functioning of gene via change in the nucleotide sequence either 
by insertion or deletion or Single nucleotide polymorphism (SNP). 
Epigenetic factors 
Epigenetic factors don’t change the sequence of DNA, occur in various cancers affect 
transcription of various genes act by DNA and Histone modification or ncRNA (miRNA) 
mediated target repression. The transcriptional regulation of miRNAs in association with SNP 
remains an unexplored area in many cancer types including ovarian cancer. 
Single nucleotide polymorphisms (SNP) 
 
Single nucleotide polymorphisms (SNPs) are common type of genetic variation known to be 
associated with many diseases.  Each SNP cause a single change in a DNA building block 
(Nucleotide). For instance- a SNP may replace the nucleotide thymine (T) with the nucleotide 
cytosine (C) in a certain stretch of DNA. Throughout DNA SNPs are present. once in every 300 
nucleotides on average the SNPs are found, There are approximately 10 million SNPs in the 
human genome (Shastry, 2002). Generally in the DNA level between genes these variations are 
found. They can act as biological markers, helping scientists to find genes with genetic variation 
that are associated with any abnormal condition like cancer. They may play a direct role in 
disease by affecting the gene When SNPs present within a gene or in a regulatory region. 
(Shastry, 2009) 
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Figure-3. Single nucleotide polymorphism 
 
Polymorphism at the DNA level has been playing an increasing factor in animal genetic studies. 
Amongst others, the microsatellite DNA marker has been the most marker type, named SNP, for 
Single Nucleotide Polymorphism, is now on the scene and has gained high recognition, even 
though it is only a bi-allelic type of marker (Vignal et al., 2002). DNA sequence is formed by a 
chain of 4 nucleotide bases: A, T, C and G. The variation can be categorized as SNP if more than 
1% of a population does not have the same nucleotide at a specific location in the DNA 
sequence. The gene is defined as having more than one allele if a SNP present within a gene. 
Variations in the amino acid sequence caused by SNPs. SNPs are also present in noncoding 
regions of DNA (Ramensky et al., 2002). A specific SNP may not responsible for a disorder but 
some SNPs are associated with certain diseases. Scientists may study stretches of DNA near 
SNPs in an attempt to classify the gene or genes responsible for the trait if certain SNPs are 
recognized to be associated with a trait. 
Despite this, a Single nucleotide polymorphism can present in two regions known as- 
1. Coding region      2. Non region  
Changes in translational product takes place if a SNP lies in the coding region of a gene i.e. 
protein formed. This phenomenon can again be by two types- non-synonymous and synonymous. 
Synonymous region don’t affect the protein sequence while   non synonymous region cause 
changes in the change amino acid sequence ultimately affecting the protein conformation 
(Cargill et al., 1999). Again non-synonymous change can occur in missense codon and nonsense 
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codon. In missense codon change results in different amino acid and non-sense codon are known 
as premature stop codon. 
In the case where mutation (SNPs) lies in noncoding regions, gene expressions are likely to get 
affected in other way. Generally non-coding regions such as 5’UTR, 3’UTR, introns, intergenic 
Regions are known to be associated with gene splicing mechanism , regulatory miRNA binding 
mechanism, mRNA degradation processes etc. all together contributing to regulation of target 
gene expression. 
 
Because of the population specific occurrence of SNPs, these are generally used to find the 
genetic similarity among a population. The genetic variation caused by the presence of SNP can 
be implicated in finding the disease causing gene that can be further used as a disease biomarker. 
The variability in drug response among different population can be studied on the basis of 
presence of specific SNPs. 
SNPs AND CANCER 
Genetic variation in human genome is emerging resource for finding out cancer, a complex set of 
diseases defined by each genetic and environmental factor.  The common germ-line variant’s 
quality is great, on the order of 10 million per person and shows a remarkable chance to analyze 
the etiology, interindividual variations in treatment response and outcomes of specific cancers 
types. The critical determinants in environmental exposure will clarify by study of genetic 
variation and cancer that may have future implications for preventive and early intervention 
procedures. (Erichsen and Chanock, 2004). 
SNPs AND OVARIAN CANCER 
There are sample of studies like Genome wide association studies screening the role of SNPs in 
the occurrence of ovarian cancer. One such study indicates the risk of gynecological cancer and 
the association of  SNP rs763110 . The results suggested that the FASL  polymorphism may 
decrease the risk of gynecological cancer (Zhou et al., 2015). Another report shows single-
nucleotide polymorphisms (SNPs) present on chromosome at position 5p15results TERT and 
CLPTM1L mutation and significant role in endometrial cancer (Carvajal-Carmona et al., 2015). 
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The rs231775 allele present in the coding region association results in change of amino acid in 
CTLA4 finally contributing to ovarian cancer. SNPs seem to play a vital role in ovarian cancer 
survival, mainly in patients with endometrioid epithelial ovarian cancer and clear cell has been 
reported sometimes acting as biomarker of ovarian Oncogenesis (Charbonneau et al., 2014). The 
union of genetic variants in the FGF (fibroblast growth factor) pathway in therapeutic reaction of 
ovarian cancer has been elucidated with the discovery of SNPs through FGF-FGFR pathway 
(Meng et al., 2014). This provides a molecular approach for monitoring therapeutic response,and 
prediction of ovarian cancer diagnosis. 
SNP regulates the miRNA targeting which additionally one of the causes of various cancers 
including Ovarian cancer types. miRNAs are known to  bind  3’ UTR or 5’UTR of target  
mRNA regulating its functioning and finally contributing to different cellular activities like 
growth control, differentiation as well as  human disease like cancer (Saunders et al., 2007). SNP 
affects the miRNAs binding when in a miRNA target site thus altering the miRNA mediated 
regulation machinery. According to the current annotation study of miRNA gene and SNP 
provide the detail of modification of miRNA targeting done by SNP. Present of SNP in seed 
region can change the miRNA-mRNA targeting either by creation or destruction of binding site 
thus affecting the protein translation mechanism (Mallick and Ghosh, 2011). 
microRNA 
MicroRNAs are newly discovered class of non-coding RNAs that have key roles in the gene 
expression regulation.  The miRNAs are small  20-22 nucleotide long single stranded  noncoding 
RNA which  takes part in posttranscriptional gene silencing process.  miRNAs play major role in 
different biological events such as differentiation, organogenesis, apoptosis ,cell proliferation 
and tumorigeneseis process (Hwang and Mendell, 2007). The aberrant expression and 
deregulation of miRNA making it unable to bind with 3’UTR of the target mRNAs are 
concerned in risk of various diseases such as tumorigeneseis. miRNAs  target more than 30% 
human genes (Lewis et al., 2005). 
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miRNA are mainly encoded in intergenic regions or protein coding genes . Intergenic miRNA  
transcription of from primary miRNA takes place by the catalyst activity of RNA polymerase II 
and RNA polymerase III (Morlando et al., 2008). miRNA present at intron  are co-transcribed 
with their host genes (Wang et al., 2009). Many proteins and enzymes are involved in biogenesis 
of miRNA such as- two enzymes known as Drosha and its subunit DGCR8 who participate in 
cleavage of pri-miRNA transcript and generate a hairpin precursor within the nucleus, known as 
pre-miRNA (Han et al., 2004). Hairpin stem pri-miRNA contain thirty three base pairs with 
terminal loop and upstream of the hairpin and also at downstream. Drosha slice eleven 
nucleotide away from hairpin base , known as a identification part for DGCR8 binding that 
determines Drosha cleavage site .  The  pri-miRNA loops additionally act as a binding site for 
nuclear ribonucleoprotein A1 sometime. After  finishing the action of Drosha, pre-miRNA is 
then exported from nucleus to the cytoplasm by a nuclear transport receptor complex known as 
expotin-5-RanGTP. For formation multiple category of small non-coding RNA  dicer acts as 
catalysis. Dicer is aided by trans- activation responsive RNA-binding protein additionally known 
as TRBP within the mammals system. Inside the cytoplasm dicer with few accessory protein 
processed this pre-miRNA into mature 22 nt miRNA and the method of miRNA biogenesis is 
completed.  Then in next step pre-miRNA with Argonaut protein for mRNA targeting  forms the 
RNA inducing silencing complex (RISC) (Murchison and Hannon, 2004). Throughout the 
loading process ,Argonaut protein cleaved non-guided strand. Ago protein  take part in gene 
silencing pathway and among various species it is conserved. 
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Figure-4. miRNA biogenesis pathway(Adopted from en.wikipedia) 
Mature miRNA target the mRNA and direct mRNA translational repression and destabilization. 
2-6 nucleotides of miRNA that binds with mRNA is known as the Seed region explained by base 
pairing rule of Watson and crick (Brodersen and Voinnet, 2009). For miRNA target recognition 
the Seed region is the most important site. Some basic characteristics as well as requirement of 
miRNA binding are- (i) presence of binding position  that should away from the center of UTR 
region, (ii) occurrence of A-U rich nucleotide composition near the target region, (iii) feasibility 
of mRNA UTR regions making it available for miRNA binding (iv) presence of multiple site for 
a specific miRNA known to have greater effect in regulation.  
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There are basically 3 types of target site such as- canonical site, marginal site, and atypical site.  
The canonical sites can be again categorized as- (a) 7mer-A1 site : designated with  2-7 
nucleotides from the 5’ end ,along with presence Adenine(A) is in target mRNA  at 1st position 
of miRNA binding, (b) 7mer-M8 : with binding position from  2 to 8 in miRNA and  (c) 8mer : 
having  2-8 base pairing  with the presence Adenine(A)  is on the target mRNA corresponding to 
first 1st position of miRNA. Likewise marginal site can be of two types-(i) 6mer: with 2-7 base 
pairing and (ii) offset 6mer: having 3-8 base pairing with the target transcript. The atypical site 
can also be categorized in to two such as 3’Supplementary site and 3’compensatory pairing that 
provide additional pairing support to the miRNA binding (Friedman et al., 2009). Different types 
of investigational confirmation has proved that 3’supplementary pairing in increasing affinity of 
seed pairing and  the binding specificity. Whereas in case of compensatory site the  Watson-crick 
pairing usually centering on miRNA nucleotide 12-16 can balance for seed mismatch and 
thereby make a functional site for binding. In a seed region miRNA has many binding sites but 
8mer binding site is the most efficient bindind site (Bartel, 2009). 
 
Figure-5. Binding efficiency of target sites shown in increasing order from top to bottom 
Our present study aimed on investigating the impact of SNPs residing within 3/UTRs of genes 
associated with ovarian cancer (OC) on miRNA targeting and alteration in target gene pool 
which will help us to achieve a deeper insight into unexplored variables of gene regulations 
linked to development and progression of OC. To achieve this goal, the aberrantly expressed 
up‐regulated miRNAs and SNPs with 25 nts flanking on each side of the polymorphic base 
reported in OC are used for predicting targets for both wild type and mutant alleles followed by 
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identifying the potential miRSNPs by using stringent parameters of miRNA targeting such as 
seed topology, change in the hybridization energy, wobble base pairing within seed site, 3/ 
complementarity, 3/ supplementary sites, site accessibility that are that might be contributing to 
disease susceptibility and might give a clue towards tumor progression. 
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OBJECTIVES 
 
OBJECTIVE 1: DATA RETRIEVAL 
 (a) Collection of ovarian cancer specific SNPs 
 (b) Retrieval of Differentially expressed miRNAs in ovarian cancer  
 
OBJECTIVE 2-   RNA Hybrid study in order to find possible miRSNPs 
 
OBJECTIVE 3- Identification of significant miRSNP pairs  
 
OBJECTIVE 4- Functional annotation of selected pair of miRSNPs 
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MATERALS AND METHODS 
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Materials and methods 
1. Data retrieval: Collection of SNP  
 
Data retrival from literature studies carried out to find those differtially expressed single 
nucleotide polymorphisms(SNPs) reported by different GWAS studies associated with ovarian 
cancer  at different population. SNPs obtained were found to be present in different genic regions 
such as exon, 3’UTR, 5’UTR, intron, CDS. The sequence information of the SNPs were  
retrieved from dbSNP database, literature and SNPedia. Then the SNPs present in 3’UTR region 
which is known to be the potential binding site of miRNAs were  consider for further validation.  
 
2. Expression data mining:  
 
2.1. Gene Expression Data: 
 
Genome wide analysis of miRNAs from normal and diseased sample in ovarian cancer was done 
in order to differentiate between different expression pattern for diagnosis and therapeutic 
mechanisms from GEO (Gene Expression Omnibus) database. 
Gene Expression Omnibus is a data base from where the expression data can be retrieved 
resulting from different experimental procedure such as microarray, small RNA sequencing etc. 
A collection of web based interfaces and applications are available for downloading gene 
expression data for different disease from GEO database.  
The miRNA expression data of the ovarian cancer and corresponding normal control sample was 
taken for analysis. 
 
2.2.  Microarray analysis of gene Expression Data: 
 
All samples of ovarian cancer (37 endometriod, 41 serous, 13 mucinous, 8 clear cell) and normal 
control (i.e. all GSMs) present in the GSE were taken for analysis. The basic steps include: 
· Data were taken from GEO dataset in multiples to decrease error. 
· Raw data files were downloaded in .CEL format. 
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· The files were kept in  unzipped folder, extracted and renamed as test  and control for 
both mRNA and miRNA . 
 
3. Analysis of Gene Expression Data: 
 
For miRNA expression analysis  Agilent’s GeneSpring GX 12.6 software was used. This is a 
microarray expression data analysis tool for analysis and fast visualization of different 
microarrays (genome copy number ,gene, miRNA, exon etc). This tool is designed for satisfying 
the requirements of biologists. Performing work in GeneSpring GX 12.6 is organized into 
projects. Number of experiments are involved in a project and an experiment is composed of 
samples (data sources). Samples are grouped as control and test. Interpretations were done based 
on the defined parameters of sample grouping and finally analysis involves a number of 
statistical steps and corresponding results. 
In Genespring GX all information about microarray design and biological information is found. 
Initially for each new array type which is to be analyzed, a new technology must be installed. 
Technologies created include affymetrix for standard arrays, Agilent and Illumina. In Gene 
Spring analysis there are following steps- 
(a)Gene expression analysis: 
In order to minimize the systematic non-biological differences and to reveal true biological 
differences, normalization of data was done, after which profile plot of normalized intensity map 
values are obtained. To standardize each chip for cross comparison, data is normalized to 75 
percentile of signals intensity. The main purpose is to eliminate redundancy and make sure that 
the data makes sense with minimum number of entities. 
 
For analysis of gene expression a new experiment was created. The experiment type should be 
specified as Affymetrix. Workflow selected was Guided Workflow. Using choose sample option 
is the unzipped samples were uploaded to the experiment from the saved location in the system. 
Experimental grouping was done to define samples as test and control and assigning a parameter 
name (e.g. Average). By using Filter Probsets by Errors, quality control of samples was done. 
This was done on the raw signal values of all the entities. For filtering, cut off was set at 20 
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percentile of all intensity values and a profile plot of filtered entities was generated. Using the 
normalized signal values and grouped samples by active interpretation box whisker plot is 
generated. 
 
Significance analysis depending upon experiment grouping, was done by performing T-Test 
Unpaired analysis as 2 groups are there that is control and test along with replicates. For 
computing p-values Benjamin-Hochberg FDR algorithm multiple testing correction was used. 
The p-value cut off taken was ≤0.05. This reduces the number of false positives or false 
discovery rate. This multiple testing correction is least stringent. Fewer chances of false negative 
genes are there. A p-value of ≤0.05 is taken as significant. For identifying differentially genes 
among the cancerous and non-cancerous samples which are expressed above a definite threshold, 
fold change analysis is done. It gives the absolute ratio of normalized intensities between the 
average intensities of grouped sample. Fold change cut off is taken ≥2.0. Further 2D hierarchical 
clustering of the genes expressed >2.0 fold was carried out taking average linkage to classify the 
cancerous and normal control samples and a heat map was generated using CLUSTER 3.0 and 
JAVA tree view. Hierarchical clustering method arranges gene in a tree structure based on their 
similarity. If the items are similar to each other then they are connected by short branches and if 
it is dissimilar then it is connected by long braches. Genes expressed greater than 2 fold were 
exported from Gene Spring along with normalized signal values, gene symbols, entrez gene IDs 
etc. The entity list was exported as .txt file and later opened with excel for further analysis. 
(b)For miRNA expression analysis: 
miRNA expression analysis was carried out in the same project of GeneSpring, but in a new 
experiment. miRNA specific platform i.e. Illumina was chosen and further steps of analysis were 
same as that of mRNA expression analysis. The miRNAs differentially expressed greater than 2 
fold between the normal and cancerous samples were exported for further analysis. 
 
4. RNA hybrid Analysis  
Differentially expressed up‐regulated miRNAs and SNP sequences with 25 nts flanking on each 
side of the polymorphic base are used for predicting targets using our in‐house multi‐step 
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predictions tool RNAhybrid for both wild type and mutant set of sequences .It is a tool for 
finding the minimum free energy of hybridization of a long and a short RNA. 
5. Filtering out in order to find the most probable miRSNP pair 
 
The RNAhybrid list was filtered on the basis of following parameters: 
 
Change of binding site: 
Seed region is the most important factor for miRNA target anticipating a perfect or near perfect 
binding between the mature miRNA and its target. Change in binding site between the ancestral 
and mutated were designated as: Site Creation (mer to other) or Site destruction (other to mer). 
The miRSNP pairs were filtered out by above parameter with most appropriate binding site. 
 
Variation in Seed topology: 
Seed topology indicates the type of seed site present in the miRNAs. Due to the presence of SNP 
in these seed site various new seed types are supposed to be formed different from the ancestral 
one that can vary with many seed topology like 7mer, 8mer, 7merA1, offset 6mer, 6mer etc. 
Change in seed types with most potential seed topology were filtered from the existing list. 
 
MFE change: 
This is otherwise known as minimum free energy change resulting due to the miRNA binding to 
the target mRNA. We set the parameter of MFE change that should not be less than -10. Because 
inside cell miRNA targeting is done with high minimum free energy. A reasonable threshold for 
MFE is required because it is one of the important parameter that one can set to increase the 
stringency of the miRNA target duplex mimicking to the cellular context. 
 
 
 
Presence GU in the seed site: 
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Presence of GU indicates unusual pair that differs from the normal Watson crick base pairing. It 
don’t obey Watson crick principle. So presence of GU should be less (0 or 1) because occurrence 
of more   GU in the seed site can interfere with miRNA binding and base pairing. 
 
Presence of Additional binding sites beyond seed site: 
Presence of supplementary binding or compensatory binding sites e.g. in 12-17 beyond the seed 
site is known to strengthen binding of miR to the target. 
The most suitable miRSNP pairs were retrieved those who satisfied the above all parameters.  
6. Establishing 1 Gene - 1 miRNA Hypothesis 
This hypothesis was experimented by the help of database Targetscan in order to establish the 
fact that mRNA present in the pair is targeted by only one conserved miRNA which is also 
present in the pair. Target Scan predicts biological targets of miRNAs by searching for the 
presence of conserved sites that match each miRNA (Lewis et al., 2005). As an option, 
nonconserved or poorly conserved sites are also predicted. Also identified are sites with 
mismatches in the seed region that are compensated by conserved 3' pairing (Friedman et al., 
2009). In mammals, predictions are ranked based on the predicted efficacy of targeting as 
calculated using the context+ scores of the sites. Here we searched the target of conserved 
sequence of miRNA with our gene of interest. Target Scan provides accurate rankings of the 
predicted targets for each miRNA.  
6. Searching for presence of other binding site for the miRNA in the target beyond 
miRSNP binding site 
· RNAhybrid is a tool for finding the probable miRNA-mRNA binding site with 
appropriate parameters. 
· In order to find other binding sites of miRNA, first we retrieve the sequence of 
mature microRNA from miRbase, a database of published miRNA sequences and 
annotation. 
· Then we collected 3 ‘UTR sequence of gene of interest from NCBI in FASTA 
format. 
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· Then both the sequence were uploaded in prescribe format of RNAhybrid-BiBiserver 
with parameters like Helix constrent-2-7, MFE—10. 
8. Functional annotation through Gene Ontology Analysis  
The functional significance of selected miRSNPs were retrieved by checking through individual 
associated gene function and expression in ovarian the disease system using Metacore. 
Metacore is an integrated software suite for functional analysis of Next Generation Sequencing, 
variant, CNV, microarray, metabolic, SAGE, proteomics, siRNA, microRNA, and screening 
data. This is an advanced database for path way analysis. Metacore is based on a high-quality, 
manually-curated database of: Transcription factors, receptors, ligands, kinases, drugs, and 
endogenous metabolites as well as other molecular classes. Rich ontologies for diseases and 
processes with hierarchical or graphic output. By the help of Metacore we got various function 
and regulation of our gene of interest present in the miRSNP in ovarian cancer system. 
Additionally extensive literature search was done separately for the functional significance of the 
pair in various other systems including ovarian cancer. 
The expression pattern of the genes were collected from Oncomine, a cancer-profiling database 
containing published data that has been collected, standardized, annotated and analyzed by 
Compendia Bioscience. Oncomine currently includes gene expression and sample data from 500 
cancer types and a wide range of cancer-related cell lines. There are more than 490 datasets and 
nearly 40,000 measured samples, including cell line panels representing published datasets and 
microarray experiments, respectively. Experimental details and sample facts are collected from 
supplemental data and direct correspondence with authors of published work and added to the 
database to drive new analysis. The data are normalized and analyzed using standard protocols, 
and presented to the end-user of Oncomine through a web-based interface. From this database 
we got information about our gene of interest in ovarian cancer cell line. 
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RESULTS AND DISCUSSIONS 
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Results & Discussions           
1. List of SNP present in 3’UTR 
132 SNP associated with ovarian cancer retrieved from literature, dbSNP, SNPedia. From 132 
snp only 22 SNP are present in 3ÚTR location. (Table1) 
SNP Allele GENE Location Source 
rs3733336 G/A FGF5 3' UTR PMID: 24146310 
rs3781699 A/C LRRC32 3' UTR PMID: 23894717 
rs1052587 C/T MAPT 3' UTR PMID: 23535648 
rs17574361 A/G KANSL1 3' UTR PMID: 23535648 
rs4640231 C/G CRHR1 3'UTR PMID: 23535648 
rs16917496 C/T SET8 3' UTR PMID: 22867998 
rs61764370 T/G KRAS 3' UTR PMID: 20647319 
rs1042364 G/A ADH4 3' UTR PMID: 21480392 
rs6990375 G/A SULF1 3' UTR PMID: 21214932 
rs13420827 G/C DNMT3A 3' UTR PMID: 18381459 
rs5275 C/T PTGS2 3' UTR PMID: 20559705 
rs608995 T/A PGR 3'UTR PMID: 20547493 
rs10131 G/A LIG4 3' UTR PMID: 20386703 
rs2278414 G/A ZBRK/ZNF350 3' UTR PMID: 20306497 
rs11169571 T/C ATF1 3' UTR PMID: 19950226 
rs1425486 T/C PGDFC 3' UTR PMID: 21118967 
rs2069414 C/A CDK2 3' UTR PMID: 19258477 
rs1053578 T/C ACBD4 3' UTR PMID: 20111712 
rs1053578 T/C ACBD4 3'UTR PMID: 20111712 
rs1425486 T/C PDGFC 3'UTR PMID: 21118967 
rs2069414 C/A CDK2 3'UTR PMID: 19258477  
rs608995 T/A PGR 3'UTR PMID: 15632380 
     
 
Table 1- List of SNPs In 3’utr 
 
 2. Microarray Analysis 
Agilent’s GeneSpring GX 12.6 software was used for gene expression analysis. This software is 
a powerful microarray expression data analysis tool for fast visualization and analysis of miRNA 
as well as mRNA Microarrays. Class of transcripts showing expression pattern which are 
correlated with experiment variables are identified by using this software. The expression 
analysis of differentially expressed miRNAs were retrieved and is shown in following clustering 
diagram. 
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Figure-6 . Clustered analysis showing DE mRNAs in Clear cell ovarian carcinoma 
 
           
 
Figure-7. Clustered analysis showing DE mRNAs in Endometrioid ovarian carcinoma 
 
31  
 
 
    
 
Figure-8. Clustered analysis showing DE mRNAs in Mucinous ovarian carcinoma 
 
             
Figure-9. Clustered analysis showing DE mRNAs in serous ovarian carcinoma 
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Figure-10. Clustered analysis showing DE miRNAs in ovarian carcinoma 
3. Result of RNAhybrid  
We took 23 SNP (3’UTR) AND 149 up regulated miRNA express in ovarian cancer for 
RNAhybrid analysis. From RNAhybrid analysis we got 137 pair of miRNA-SNP. RNAhybrid 
was run to study interaction among the chosen up regulated miRNA and 3’UTR SNP pair. 
 
4. Filtered most Probable miRSNPs 
 
From 137 pair obtained from the RNA Hybrid, 46 miRSNPs were filtered on the basis of 
different parameters like- change of binding site, variation in Seed topology, MFE change, 
presence GU in the seed site and Presence of Additional binding sites beyond seed site. Among 
46 pair of miRSNP, 27 pair were with new site creation and 19 sites with destruction of sites as 
compared to the ancestor allele.  
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                                                         Table 2   significant miRSNP pair 
5. Expression pattern of genes in selected miRSNPs from Oncomine  
 
 
  
 
 
 
 
 
 
Figure-11. Elevated expression of kRAS in ovarian cancer 
SNP-gene miRNA  Change in seed type Seed Type   
rs1053578_ACBD4  hsa-miR-28-5p  Site creation   Other-7mer-m8 
rs11169571_ATF1  hsa-miR-340-5p  Site creation  Other-7mer-m8 
rs13420827_DNMT3A  hsa-miR-155-5p  Site creation Other-7mer-m8 
rs1052587_MAPT  hsa-miR-199a-5p  Site creation Other-6mer 
rs5275_PTGS2  hsa-miR-129-5p  Site creation  Other-6mer 
rs2069414_CDK2  hsa-miR-206  Site destruction 6mer-other 
rs1425486_PGDFC  hsa-miR-218-5p  Site destruction 7mer-other 
rs61764370_KRAS  hsa-miR-223-5p Site destruction 6mer-other 
rs1052587_MAPT  hsa-miR-133a-5p  Site destruction 7mer-A1-other 
rs2069414_CDK2  hsa-miR-183-5p  Site destruction 7mer-A1-other 
rs2069414_CDK2  hsa-miR-1  Site destruction 6mer-other 
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Figure-12. Elevated expression of CDK2 in ovarian cancer 
6. Functional implication Putative miRSNPs 
(a) rs61764370_kRAS- has-miR-223-5p 
 This miRSNP obtained was with destruction of binding site due to presence of SNP in the 
3’UTR of kRAS. Thus with destruction of existing site in the mutated allele, the miRNA is 
unable to target and the target transcript is now free from the RNA silencing machinery of the 
miRNA thus having elevated expression in OC. The expected expression of the transcripts was 
co-related with that of our Oncomine result. 
Kirsten rat sarcoma (KRAS) viral oncogene homolog belongs to a class of known oncogenes. 
When mutated, oncogenes have the potential to cause normal cells to become cancerous. The 
KRAS gene is in the Ras family of oncogenes. These proteins play important roles in cell 
division, cell differentiation, and the self-destruction of cells (apoptosis).Some gene mutations 
are acquired during lifetime and are present only in certain cells. These changes, which are called 
somatic mutations, are not inherited. Somatic mutations in the KRAS gene are involved in the 
development of several types of cancer. The KRAS-variant is an inherited, germline variant that 
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has been demonstrated to serve as a genetic marker of increased risk of OC (Keane and Ratner, 
2010). 
 
 
 
 
 
 
 
 
Figu
re-13. Networks showing KRAS & regulating downstream partners in OC 
Gene  Object Type Patners Partner Type Effect Mechanism 
K-RAS RAS - 
superfamily 
Tiam1 Regulators (GDI, GAP, 
GEF) 
Activation Binding 
K-RAS RAS - 
superfamily 
c-Raf-
1 
Protein kinase Activation Binding 
 
Table 3 CDK2 regulating other downstream interacting partners 
(b) rs2069414_CDK2-has-miR-183-5p 
The RNA Hybrid result for this miRSNP showed the destruction of binding site for this miRNA 
thus making the transcript CDK2 free from RNA silencing mechanism. Thus we hypothesize the 
over expression of CDK2 as shown in the Oncomine output is may be due the SNP causing the 
destruction target site for the miRNA. 
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Cyclin dependent kinases (Cdks), a family of serine kinases, faithfully control the mammalian 
cell cycle by binding to cyclins. Cdks play a key role in controlling the cell cycle, a process 
whose dysregulation can potentially lead to uncontrolled cell growth and leads to cancer.  Cyclin 
E binds G1 phase Cdk2, which is required for the transition from G1 to S phase while binding 
with Cyclin A is required to progress through the S phase. Its activity is also regulated by 
phosphorylation. In normal cell CDK2is inhibited after one cell cycle while case of cancer cell 
the action of CDK2 is always high. 
 
Figure-14. Networks showing CDK2 regulating downstream partners in OC 
 
 
 
 
37  
 
 
Gene  Object Type Patners Partner Type Effect Mechanism 
CDK2 Protein kinase PR (nuclear) 
Transcription 
factor Activation Phosphorylation 
CDK2 Protein kinase p130 Generic binding protein Inhibition Binding 
CDK2 Protein kinase NEK1 Protein kinase Unspecified Phosphorylation 
CDK2 Protein kinase SMAD3 Transcription factor Inhibition Phosphorylation 
CDK2 Protein kinase Lyn Protein kinase Unspecified Phosphorylation 
CDK2 Protein kinase SKP2 Generic binding protein Inhibition Phosphorylation 
CDK2 Protein kinase p21 Generic binding protein Inhibition Phosphorylation 
CDK2 Protein kinase FKHR Protein Inhibition Phosphorylation 
CDK2 Protein kinase p27KIP1 Generic binding protein Inhibition Phosphorylation 
CDK2 Protein kinase E2F1 Transcription factor Inhibition Phosphorylation 
CDK2 Protein kinase Rb protein Generic binding protein Inhibition Phosphorylation 
CDK2 Protein kinase ESR1 (nuclear) 
Transcription 
factor Activation Phosphorylation 
CDK2 Protein kinase Cyclin E Generic binding protein Inhibition Phosphorylation 
 
Table-4. CDK2 regulating other downstream interacting partners 
The targetscan analysis employed for establishing one gene-one miRNA hypothesis showed the 
possibility of another up regulated miRNA (has- miR-155) from our set with conserved binding 
site for the KRAS gene. But our further analysis showed this miRNA has another probable target 
i.e. DNMT3A (DNA Methyl transferase 3A) which was also found to have low expression in OC 
as resulted from Oncomine. Thus we hypothesize the  low expression of DNMT3A may be due 
to has-miR-155 binding , which indicated that DNMT3A may be acting as a ceRNA 
(competitive endogenous RNA) against KRAS competition for the same  miRNA. 
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Figure-15. Low expression of DNMT3A in OC 
 Further analysis of the miRSNP pair in order to find out other binding site for the same miRNA 
present in the pair using RNA Hybrid (BB server) showed additional single binding site in the 
3’UTr of the respective genes both for KRAS and CDK2. This result indicates loss of additive 
effect of the in the UTR because of destruction of previously existing site due to SNP thus 
making the miRNA less effective in targeting the corresponding mRNAs. 
 
Figure-16. RNA hybrid showing additional binding site for KRAS-miR-223-5p pair 
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Figure-17. RNA hybrid showing additional binding site for CDK2-miR-183-5p pair 
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CONCLUSIONS 
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Conclusions 
Our present study resulted in identification of two putative miRSNPs having functional 
significance in ovarian tumorigeneseis. From 137 pair obtained from the RNA Hybrid, 46 
miRSNPs were filtered on the basis of different parameters like- change of binding site, variation 
in Seed topology, MFE change, presence GU in the seed site and Presence of additional binding 
sites beyond seed site. In rs61764370_kRAS-hsa-miR-223-5p miRSNP obtained, destruction of 
binding site was observed due to presence of SNP in the 3’UTR of KRAS. Thus with destruction 
of existing site in the mutated allele, the miRNA is unable to target making KRAS free from the 
RNA silencing machinery of the miRNA thus having elevated expression in OC. Similarly RNA 
Hybrid result for miRSNP rs2069414_CDK2-hsa-miR-183-5p showed the destruction of binding 
site for this miRNA. Thus we hypothesize the over expression of CDK2 as well as KRAS may 
be due the SNP causing the destruction target site for respective miRNA. The functional 
significance of the pair was obtained from the GO ontology analysis by Metacore showed the 
regulatory aspect of KRAS and CDK2 interacting with other downstream molecule thus making 
the two genes to act as a hub in the biological network.  
In future work the target validation of the miRSNPs can be done through luciferase assay. In 
addition to that, by silencing this genetically variable genes contributing to the cancer 
progression can be implemented in therapeutic prevention of this disease. 
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